Event Date

December 5-7, 2019

Event Location

Singapore

Send us an email

Cecilia@istci.org

Register Now!

Save $200 for Earlybird

 
Latest News

•  Online Registration is Open
March 1st, 2019

•  Call for speakers!
February 1st, 2019

•  Save $200 for Earlybird Registration before April 30th, 2019

 
Important Dates

•  Abstract Submission Start Day
February 1st, 2019

•  Earlybird Registration Start Day
March 1st, 2019

•  Earlybird Registration Deadline
April 30th, 2019

•  Abstract Submission Deadline
October 15th, 2019

•  Acceptance Notification Deadline
November 5th, 2019

 
 


 

Welcome Message

 

On behalf of the Organizing Committee, it gives our great pleasure to welcome you to The International Congress of Cancer & Clinical Oncology (CCCO-2019) to be held from December 5-7, 2019 in Singapore.

CCCO-2019 mainly focuses on current hot topics of cancer research and clinical oncology to accelerate the translation of cutting edge discovery from basic science to clinical level, and further promote international scientific cooperation, debate and exchange. It aims to presents a unique platform for prominent surgeons, doctors, academician, scientists and R&D leaders from pharmaceuticals to obtain and exchange information on advances in the basic research, early diagnosis and treatment of cancer, while considering both global and regional aspects.

Through three days meeting, there will be 28 parallel sessions, as well as plenary forum for keynote speeches from distinguished researchers from worldwide, hospital management forum and Industrial Satellite Symposia. We are expecting upwards of 500 participants from all over the world to take part in this event. Poster showcase and table top will run during the same three days. We are confident that over the meeting of the three days there will be something to whet everyone's appetite!

Finally, we are looking forward to welcoming you all to this enriching and stimulating meeting. Hope you will enjoy your stay in the Singapore.

Honorary Chair

Stephen Kwok-Wing Tsui, Professor, The Chinese University of Hong Kong, Hong Kong, China

Keynote Presenters
 

Title: Diagnosis of stage I pancreatic cancer saves lives
Dr. Carl Borrebaeck, Professor and Director of CREATE Health Cancer Center, Lund University, Sweden

Biography:
Professor Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1989, when the Department was inaugurated. His main research interests are cancer proteomics, for early detection and prognosis, antibody engineering, for the generation of human therapeutic antibodies and mechanisms and prediction of allergy.

Professor Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. Today Professor Borrebaeck is scientific director of CREATE Health a center for Translational Cancer Research at Lund University, where the focus is to work with complex clinical problems using advanced technologies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research!Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. 2017 he was awarded as Biotech Builder of the year.
Professor Borrebaeck´s research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB and SenzaGen AB, focusing on different aspects of diagnosis or therapy of complex diseases. View More at  http://www.immun.lth.se/research/principal-investigators/carl-borrebaeck/biography/

Title: Imaging in Bone Metastases in Prostate Cancer

Dr. Werner Langsteger, Director, Nuclear Medicine & PET CT Center Linz, St Vincent's Hospital, Austria

Biography:

Prof Dr Langsteger completed his Board Certification in Nuclear Medicine & Endocrinology and Internal Medicine 1994. He is the Director of the Department of Nuclear Medicine & Endocrinology and the PETCT Center Linz and Thyroid Center Linz since 1998.

He was member of the Executive Committee of the EANM (European Association of Nuclear Medicine) 2009 – 2012. He was President of the Austrian Society of Nuclear Medicine 2012 – 2015. Most recently, he is the President of the AASHP (Austrian Association of Senior Hospital Physicians).

Title: Move from Reductionism to Complex Biology and Development of Next Generation Therapies in Oncology

Dr. Harsukh Parmar, Non-Executive Director, Innovator, Entrepreneur & Consultant to The Biotech Industry, UK & USA

Biography:
Harsukh qualified in Medicine at Aberdeen University and worked at the Imperial medical school for 10 years in academic medicine, immunology and oncology. He later worked for Pfizer, Roche, AstraZeneca & Merck Kga in various senior leadership roles.

and has transitioned more than 120 NME’s from Discovery into Development and Launch of many blockbusters (Rituximab, Voriconazole, Symbicort, Brilinta etc).  He chaired and lead the cross-functional Translational Medicine Leadership Team comprising of both discovery and development functions within AstraZeneca, Medimmune & Roche. He has served on all the major R & D governance committees at all his former companies (ESPC, DRC, DOC etc) and has chaired and been keynote speaker at more than 150 industry and academic conferences and is cited in Marquis Who Who since 1990 for his contributions to science and medicine.

Title: The Evolving Landscape of Biomarkers in Cancer Drug Development

Dr. Baolin Zhang, Senior Investigator and Lead Product Reviewer, Food and Drug Administration, Center for Drug Evaluation and Research, USA

Biography:
Dr. Baolin Zhang is a Senior Investigator in the Office of Biotechnology Products of the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA).

Dr. Zhang has 18 years of FDA regulatory experience with extensive and practical knowledge in the development and market approval of biotech products (therapeutic proteins, monoclonal antibodies, ADCs, biosimilars). He also directs multidisciplinary research programs to support regulatory decision making and is Subject Matter Expert for cancer drug development. Dr. Zhang has authored more than 200 peer-reviewed articles, book chapters, and presentations on topics related to cancer drug resistance, cancer biomarker, targeted therapy, and product quality issues. Dr. Zhang received numerous awards including the FDA Scientific Achievement Award and FDA Awards for Excellence in Regulatory Science, Excellence in Analytical Science, Excellence in Mentoring, Excellence in Leadership, and Team Excellence.

Title: Quantitative Metabolomic Phenotyping of Cancer Cells

Dr. Huiru Tang, Distinguished Professor, School of Life Science and Zhongshan Hospital, Fudan University, China

Biography:

Dr. Tang received a bachelor's degree from Northwestern Light Industry College (now Shaanxi University of Science and Technology) in 1986 and a doctorate from London University in 1994. From 1992 to 2000, he successively served as Research Scientist, Senior Research Scientist at BBSRC Food Research Institute. From 2001 to 2005, he served as Senior Scientist in Biochemistry Department of Biomedical Engineering, Imperial College London. 

From 2005 to 2014, he successively served as researcher and doctoral supervisor of Wuhan Institute of Physics and Mathematics, deputy director of research department and director of Key Laboratory of Biological Magnetic Resonance Analysis of Chinese Academy of Sciences. November 2014 Fudan University Distinguished Professor.

 

Copyright © 2018-2019 ISTCI.ORG All Rights Reserved.